No Picture
News

The big shakeup at a badly rattled Biogen continues as 2 longtime board members hit the exits

In recent weeks we’ve seen Biogen’s CSO exit under pressure and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s. Now 2 longtime board members are on the way out as well as aftershocks…… Click here to view original post… […]

No Picture
News

NeuroSense Therapeutics to Present at BIO CEO & Investor Conference

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Alon Ben-Noon, NeuroSenses’s CEO will present a company overview at the BIO CEO & Investor Conference on February 15th at 9:30AM Eastern. The conference… Click here to view original post… […]

No Picture
News

Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.

WOBURN, Mass. & MIAMI–(BUSINESS WIRE)–Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred herein as “OTR”), a publicly traded special purpose acquisition company… Click here to view original post… […]

No Picture
News

Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ — Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (NASDAQ: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1 (DKK1). The assay will be used to support clinical development of Leap… Click here to view original post… […]